KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Treasury Shares (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Treasury Shares for 6 consecutive years, with $396693.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 4.9% to $396693.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $396693.0 through Dec 2025, up 4.9% year-over-year, with the annual reading at $396693.0 for FY2025, 4.9% up from the prior year.
  • Treasury Shares for Q4 2025 was $396693.0 at Supernus Pharmaceuticals, up from $393871.0 in the prior quarter.
  • The five-year high for Treasury Shares was $439216.0 in Q2 2025, with the low at $20000.0 in Q3 2023.
  • Average Treasury Shares over 5 years is $250496.6, with a median of $260633.0 recorded in 2022.
  • The sharpest move saw Treasury Shares tumbled 90.92% in 2023, then soared 1816.5% in 2024.
  • Over 5 years, Treasury Shares stood at $21110.0 in 2021, then surged by 855.71% to $201750.0 in 2022, then surged by 48.77% to $300141.0 in 2023, then increased by 26.0% to $378165.0 in 2024, then grew by 4.9% to $396693.0 in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $396693.0, $393871.0, and $439216.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.